Lymphoma, Non-Hodgkin Clinical Trials

17 studies are recruiting for lymphoma, non-hodgkin in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

   Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nod…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute ( Site 7000), Denver, Colorado

   Locations

   40 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07519772 on ClinicalTrials.gov

2. Tissue Collection for Studies of Lymph Cancer

   Background: - Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These condition…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Locations

   2 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01676805 on ClinicalTrials.gov

3. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

   The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   51 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07101328 on ClinicalTrials.gov

4. TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

   The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Medicine Cancer Center, Palo Alto, California

   Locations

   14 in total

   Run by

   Treeline Biosciences, Inc.

   See if you can join NCT07082803 on ClinicalTrials.gov

5. Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

   The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether s…

   Stage

   Not phased

   Ages

   4 and older

   Site

   Walter Reed National Military Medical Center, Bethesda, Maryland

   Locations

   3 in total

   Run by

   Henry M. Jackson Foundation for the Advancement of Military Medicine

   See if you can join NCT07652580 on ClinicalTrials.gov

6. Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

   Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT02682667 on ClinicalTrials.gov

7. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

8. eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

   The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem cell transplantation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT07469592 on ClinicalTrials.gov

9. CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

   Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: T…

   Stage

   Phase 1

   Ages

   3 to 39

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05442515 on ClinicalTrials.gov

10. Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

    This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic synd…

    Stage

    Phase 2

    Ages

    0 to 39

    Site

    University of Florida, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT05800210 on ClinicalTrials.gov

11. Epcoritamab-CAR T Cells for Large B-cell Lymphomas

    This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT06458439 on ClinicalTrials.gov

12. Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

    This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06923397 on ClinicalTrials.gov

13. Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

    This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford, Stanford, California

    Locations

    3 in total

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT06510361 on ClinicalTrials.gov

14. Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

    The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stanford University School of Medicine, Stanford, California

    Run by

    Stanford University

    See if you can join NCT00398177 on ClinicalTrials.gov

15. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    St Vincent's Hospital, Darlinghurst, New South Wales

    Locations

    16 in total

    Run by

    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov

16. Family Study of Lymphoproliferative Disorders

    Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic …

    Stage

    Not phased

    Ages

    18 to 100

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT00626496 on ClinicalTrials.gov

17. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

    This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will incl…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Davis, Sacramento, California

    Locations

    2 in total

    Run by

    Estrella Biopharma, Inc.

    See if you can join NCT06343311 on ClinicalTrials.gov